CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease

Uroosa Ibrahim; Claude Bassil; Julio C. Chavez; Farhad Khimani; Michael D. Jain; Frederick L. Locke; Keren Osman; Aleksandr Lazaryan

doi:10.1016/j.clml.2023.05.007

CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease

Uroosa Ibrahim
, Claude Bassil
, Julio C. Chavez
, Farhad Khimani
, Michael D. Jain
, Frederick L. Locke
, Keren Osman
, Aleksandr Lazaryan

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

• CAR T cell therapy can be a safe an effective treatment option for post-transplant lymphoproliferative disorder. • Careful management of immunosuppressive medications before and during the treatment period is required to prevent graft rejection. • Low dose of immunosuppression during CAR T cell therapy can be maintained and may not affect efficacy. • A multidisciplinary team approach throughout the process is essential.

Original language	English
Pages (from-to)	772-778
Number of pages	7
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	23
Issue number	10
DOIs	https://doi.org/10.1016/j.clml.2023.05.007
State	Published - Oct 2023

Keywords

Cellular therapy
Diffuse large B cell lymphoma
Liver transplant
Organ rejection
Renal transplant

Access to Document

10.1016/j.clml.2023.05.007

Cite this

@article{199e3df6a72c4c599559a024e1542b28,

title = "CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease",

abstract = "• CAR T cell therapy can be a safe an effective treatment option for post-transplant lymphoproliferative disorder. • Careful management of immunosuppressive medications before and during the treatment period is required to prevent graft rejection. • Low dose of immunosuppression during CAR T cell therapy can be maintained and may not affect efficacy. • A multidisciplinary team approach throughout the process is essential.",

keywords = "Cellular therapy, Diffuse large B cell lymphoma, Liver transplant, Organ rejection, Renal transplant",

author = "Uroosa Ibrahim and Claude Bassil and Chavez, \{Julio C.\} and Farhad Khimani and Jain, \{Michael D.\} and Locke, \{Frederick L.\} and Keren Osman and Aleksandr Lazaryan",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

month = oct,

doi = "10.1016/j.clml.2023.05.007",

language = "English",

volume = "23",

pages = "772--778",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Elsevier Inc.",

number = "10",

}

TY - JOUR

T1 - CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation

T2 - A Safe and Feasible Therapy for an Orphan Disease

AU - Ibrahim, Uroosa

AU - Bassil, Claude

AU - Chavez, Julio C.

AU - Khimani, Farhad

AU - Jain, Michael D.

AU - Locke, Frederick L.

AU - Osman, Keren

AU - Lazaryan, Aleksandr

PY - 2023/10

Y1 - 2023/10

N2 - • CAR T cell therapy can be a safe an effective treatment option for post-transplant lymphoproliferative disorder. • Careful management of immunosuppressive medications before and during the treatment period is required to prevent graft rejection. • Low dose of immunosuppression during CAR T cell therapy can be maintained and may not affect efficacy. • A multidisciplinary team approach throughout the process is essential.

AB - • CAR T cell therapy can be a safe an effective treatment option for post-transplant lymphoproliferative disorder. • Careful management of immunosuppressive medications before and during the treatment period is required to prevent graft rejection. • Low dose of immunosuppression during CAR T cell therapy can be maintained and may not affect efficacy. • A multidisciplinary team approach throughout the process is essential.

KW - Cellular therapy

KW - Diffuse large B cell lymphoma

KW - Liver transplant

KW - Organ rejection

KW - Renal transplant

UR - https://www.scopus.com/pages/publications/85160749532

U2 - 10.1016/j.clml.2023.05.007

DO - 10.1016/j.clml.2023.05.007

M3 - Article

AN - SCOPUS:85160749532

SN - 2152-2650

VL - 23

SP - 772

EP - 778

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 10

ER -

CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease

Abstract

Keywords

Access to Document

Fingerprint

Cite this